Latest News and Press Releases

EpiCept Announces Initiation of Phase 2B Study of Azixa™ for Front-Line Treatment of Glioblastoma Multiforme by Myrexis   TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory...

EpiCept Announces Ceplene® Approved for Marketing in Israel Additional Marketing Approval Applications Anticipated in 2011 TARRYTOWN, N.Y.--(BUSINESS...

EpiCept Announces Initiation by NCI of Phase II Trial with Crolibulin™ in Anaplastic Thyroid Cancer TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept...

EpiCept Reports New Analysis Supports Ceplene's Favorable Impact on Overall Survival TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- EpiCept Corporation (Nasdaq and Nasdaq OMX...

EpiCept Announces Ceplene® Poster Presentation at the 52nd Annual Meeting of the American Society of Hematology TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory...

EpiCept Corporation to Present at the NYSSA Biotech and Specialty Pharmaceuticals Conference TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept Corporation...

EpiCept Corporation Reports Third Quarter 2010 Operating and Financial Results CONFERENCE CALL BEGINS AT 9:00 A.M. EASTERN TIME TARRYTOWN, N.Y.--(BUSINESS...

EpiCept Raises $2 Million via Registered Direct Financing TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept Corporation (Nasdaq and OMX Stockholm Exchange:...

EpiCept Provides Update on Its 2011 Financing Plan GRANTED FUNDING THROUGH U.S. QUALIFYING THERAPEUTIC DISCOVERY PROJECT PROGRAM TARRYTOWN, N.Y.--(BUSINESS...

EpiCept to Report Third Quarter 2010 Operating and Financial Results on November 9, 2010 TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept Corporation...